secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-08-17T12:00:30+00:00
Accession:  0001437749-26-028111
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Q2 2026: net loss $18M, cash $26.7M; FDA ketamine ANDA only needs attestation
--------------------------------------------------------------------------------

- FDA review of ANDA for preservative-free ketamine found no drug-related major deficiencies; only manufacturer's attestation submitted, aiming for 2026 approval.
- Closed underwritten public offering for gross proceeds of $22.3M; cash at June 30, 2026 was $26.7M vs $7.8M at Dec 31, 2025.
- Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS; non-dilutive funding >$11.5M.
- Appointed Glenn Tyson as first Chief Commercial Officer; initiated commercial scale manufacturing of 5M ketamine doses.
- Net loss for six months ended June 30, 2026 was $18.0M vs $23.1M in 2025; net operating loss $11.3M vs $7.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/0001437749-26-028111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/nrxp20260817_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-028111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer